FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation

Sangeeta Pande, Cynthia S. Ritter, Marcos Rothstein, Karen Wiesen, John Vassiliadis, Rajiv Kumar, Susan C. Schiavi, Eduardo Slatapolsky, Alex J. Brown

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background: The phosphatonins fibroblast growth factor-23 (FGF-23) and FRP-4 are inhibitors of tubular phosphate reabsorption that may play a role in the hyperphosphatemia associated with chronic kidney disease (CKD) or in the hypophosphatemia associated with renal transplants. Methods: Plasma FGF-23, FRP-4, phosphorus and parathyroid hormone were measured in patients at all stages of CKD. Phosphate regulation of FGF-23 and secreted frizzled related protein-4 (sFRP-4) was examined in end-stage renal disease patients in the presence and absence of therapeutic phosphate binder usage. In renal transplant patients, plasma FGF-23, sFRP-4 and phosphorus concentrations were determined before and 4-5 days after transplantation. Results: Plasma FGF-23 correlated with creatinine clearance (r2 = -0.584, p < 0.0001) and plasma phosphorus (r2 = 0.347, p < 0.001) in CKD patients and with plasma phosphorus (r2 = 0.448, p <0.001) in end-stage renal disease patients. Phosphate binder withdrawal increased FGF-23 levels. In kidney transplant patients, dramatic decreases in FGF-23 (-88.8 ± 5.4%) and phosphorus (-64 ± 10.2%) were observed by 4-5 days post-transplantation. In patients with post-transplant hypophosphatemia, FGF-23 levels correlated inversely with plasma phosphorus (r2 = 0.661, p < 0.05). sFRP-4 levels did not change with creatinine clearance or hyperphosphatemia in CKD or end-stage renal disease patients, and no relation was noted between post-transplant sFRP-4 levels and hypophosphatemia. Conclusions: In CKD, FGF-23 levels rose with decreasing creatinine clearance rates and increasing plasma phosphorus levels, and rapidly decreased post-transplantation suggesting FGF-23 is cleared by the kidney. Residual FGF-23 may contribute to the hypophosphatemia in post-transplant patients.

Original languageEnglish (US)
JournalNephron - Physiology
Volume104
Issue number1
DOIs
StatePublished - Aug 2006

Fingerprint

Chronic Renal Insufficiency
Kidney Transplantation
Phosphorus
Hypophosphatemia
Transplants
Phosphates
Chronic Kidney Failure
Hyperphosphatemia
Kidney
Creatinine
Transplantation
rat Sfrp4 protein
fibroblast growth factor 23
Parathyroid Hormone

Keywords

  • Fibroblast growth factor-23
  • Hyperparathyrodiism
  • Hypophosphatemia
  • Kidney disease
  • Matrix extracellular phosphoglycoprotein
  • Parathyroid hormone
  • Phosphate
  • Phosphatonin
  • Renal transplantation
  • Secreted frizzled related protein-4

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Pande, S., Ritter, C. S., Rothstein, M., Wiesen, K., Vassiliadis, J., Kumar, R., ... Brown, A. J. (2006). FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron - Physiology, 104(1). https://doi.org/10.1159/000093277

FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. / Pande, Sangeeta; Ritter, Cynthia S.; Rothstein, Marcos; Wiesen, Karen; Vassiliadis, John; Kumar, Rajiv; Schiavi, Susan C.; Slatapolsky, Eduardo; Brown, Alex J.

In: Nephron - Physiology, Vol. 104, No. 1, 08.2006.

Research output: Contribution to journalArticle

Pande, S, Ritter, CS, Rothstein, M, Wiesen, K, Vassiliadis, J, Kumar, R, Schiavi, SC, Slatapolsky, E & Brown, AJ 2006, 'FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation', Nephron - Physiology, vol. 104, no. 1. https://doi.org/10.1159/000093277
Pande, Sangeeta ; Ritter, Cynthia S. ; Rothstein, Marcos ; Wiesen, Karen ; Vassiliadis, John ; Kumar, Rajiv ; Schiavi, Susan C. ; Slatapolsky, Eduardo ; Brown, Alex J. / FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. In: Nephron - Physiology. 2006 ; Vol. 104, No. 1.
@article{2e537e3772894a61a19a617a12aa2a8a,
title = "FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation",
abstract = "Background: The phosphatonins fibroblast growth factor-23 (FGF-23) and FRP-4 are inhibitors of tubular phosphate reabsorption that may play a role in the hyperphosphatemia associated with chronic kidney disease (CKD) or in the hypophosphatemia associated with renal transplants. Methods: Plasma FGF-23, FRP-4, phosphorus and parathyroid hormone were measured in patients at all stages of CKD. Phosphate regulation of FGF-23 and secreted frizzled related protein-4 (sFRP-4) was examined in end-stage renal disease patients in the presence and absence of therapeutic phosphate binder usage. In renal transplant patients, plasma FGF-23, sFRP-4 and phosphorus concentrations were determined before and 4-5 days after transplantation. Results: Plasma FGF-23 correlated with creatinine clearance (r2 = -0.584, p < 0.0001) and plasma phosphorus (r2 = 0.347, p < 0.001) in CKD patients and with plasma phosphorus (r2 = 0.448, p <0.001) in end-stage renal disease patients. Phosphate binder withdrawal increased FGF-23 levels. In kidney transplant patients, dramatic decreases in FGF-23 (-88.8 ± 5.4{\%}) and phosphorus (-64 ± 10.2{\%}) were observed by 4-5 days post-transplantation. In patients with post-transplant hypophosphatemia, FGF-23 levels correlated inversely with plasma phosphorus (r2 = 0.661, p < 0.05). sFRP-4 levels did not change with creatinine clearance or hyperphosphatemia in CKD or end-stage renal disease patients, and no relation was noted between post-transplant sFRP-4 levels and hypophosphatemia. Conclusions: In CKD, FGF-23 levels rose with decreasing creatinine clearance rates and increasing plasma phosphorus levels, and rapidly decreased post-transplantation suggesting FGF-23 is cleared by the kidney. Residual FGF-23 may contribute to the hypophosphatemia in post-transplant patients.",
keywords = "Fibroblast growth factor-23, Hyperparathyrodiism, Hypophosphatemia, Kidney disease, Matrix extracellular phosphoglycoprotein, Parathyroid hormone, Phosphate, Phosphatonin, Renal transplantation, Secreted frizzled related protein-4",
author = "Sangeeta Pande and Ritter, {Cynthia S.} and Marcos Rothstein and Karen Wiesen and John Vassiliadis and Rajiv Kumar and Schiavi, {Susan C.} and Eduardo Slatapolsky and Brown, {Alex J.}",
year = "2006",
month = "8",
doi = "10.1159/000093277",
language = "English (US)",
volume = "104",
journal = "Experimental Nephrology",
issn = "1660-8151",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation

AU - Pande, Sangeeta

AU - Ritter, Cynthia S.

AU - Rothstein, Marcos

AU - Wiesen, Karen

AU - Vassiliadis, John

AU - Kumar, Rajiv

AU - Schiavi, Susan C.

AU - Slatapolsky, Eduardo

AU - Brown, Alex J.

PY - 2006/8

Y1 - 2006/8

N2 - Background: The phosphatonins fibroblast growth factor-23 (FGF-23) and FRP-4 are inhibitors of tubular phosphate reabsorption that may play a role in the hyperphosphatemia associated with chronic kidney disease (CKD) or in the hypophosphatemia associated with renal transplants. Methods: Plasma FGF-23, FRP-4, phosphorus and parathyroid hormone were measured in patients at all stages of CKD. Phosphate regulation of FGF-23 and secreted frizzled related protein-4 (sFRP-4) was examined in end-stage renal disease patients in the presence and absence of therapeutic phosphate binder usage. In renal transplant patients, plasma FGF-23, sFRP-4 and phosphorus concentrations were determined before and 4-5 days after transplantation. Results: Plasma FGF-23 correlated with creatinine clearance (r2 = -0.584, p < 0.0001) and plasma phosphorus (r2 = 0.347, p < 0.001) in CKD patients and with plasma phosphorus (r2 = 0.448, p <0.001) in end-stage renal disease patients. Phosphate binder withdrawal increased FGF-23 levels. In kidney transplant patients, dramatic decreases in FGF-23 (-88.8 ± 5.4%) and phosphorus (-64 ± 10.2%) were observed by 4-5 days post-transplantation. In patients with post-transplant hypophosphatemia, FGF-23 levels correlated inversely with plasma phosphorus (r2 = 0.661, p < 0.05). sFRP-4 levels did not change with creatinine clearance or hyperphosphatemia in CKD or end-stage renal disease patients, and no relation was noted between post-transplant sFRP-4 levels and hypophosphatemia. Conclusions: In CKD, FGF-23 levels rose with decreasing creatinine clearance rates and increasing plasma phosphorus levels, and rapidly decreased post-transplantation suggesting FGF-23 is cleared by the kidney. Residual FGF-23 may contribute to the hypophosphatemia in post-transplant patients.

AB - Background: The phosphatonins fibroblast growth factor-23 (FGF-23) and FRP-4 are inhibitors of tubular phosphate reabsorption that may play a role in the hyperphosphatemia associated with chronic kidney disease (CKD) or in the hypophosphatemia associated with renal transplants. Methods: Plasma FGF-23, FRP-4, phosphorus and parathyroid hormone were measured in patients at all stages of CKD. Phosphate regulation of FGF-23 and secreted frizzled related protein-4 (sFRP-4) was examined in end-stage renal disease patients in the presence and absence of therapeutic phosphate binder usage. In renal transplant patients, plasma FGF-23, sFRP-4 and phosphorus concentrations were determined before and 4-5 days after transplantation. Results: Plasma FGF-23 correlated with creatinine clearance (r2 = -0.584, p < 0.0001) and plasma phosphorus (r2 = 0.347, p < 0.001) in CKD patients and with plasma phosphorus (r2 = 0.448, p <0.001) in end-stage renal disease patients. Phosphate binder withdrawal increased FGF-23 levels. In kidney transplant patients, dramatic decreases in FGF-23 (-88.8 ± 5.4%) and phosphorus (-64 ± 10.2%) were observed by 4-5 days post-transplantation. In patients with post-transplant hypophosphatemia, FGF-23 levels correlated inversely with plasma phosphorus (r2 = 0.661, p < 0.05). sFRP-4 levels did not change with creatinine clearance or hyperphosphatemia in CKD or end-stage renal disease patients, and no relation was noted between post-transplant sFRP-4 levels and hypophosphatemia. Conclusions: In CKD, FGF-23 levels rose with decreasing creatinine clearance rates and increasing plasma phosphorus levels, and rapidly decreased post-transplantation suggesting FGF-23 is cleared by the kidney. Residual FGF-23 may contribute to the hypophosphatemia in post-transplant patients.

KW - Fibroblast growth factor-23

KW - Hyperparathyrodiism

KW - Hypophosphatemia

KW - Kidney disease

KW - Matrix extracellular phosphoglycoprotein

KW - Parathyroid hormone

KW - Phosphate

KW - Phosphatonin

KW - Renal transplantation

KW - Secreted frizzled related protein-4

UR - http://www.scopus.com/inward/record.url?scp=33747231852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747231852&partnerID=8YFLogxK

U2 - 10.1159/000093277

DO - 10.1159/000093277

M3 - Article

C2 - 16691036

AN - SCOPUS:33747231852

VL - 104

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 1660-8151

IS - 1

ER -